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ABSTRACT
Background: Thirty years ago very high multiple sclerosis (MS) prevalence rates were recorded in northern Scotland. We repeated a prevalence study in Aberdeen, Orkney and Shetland to see if prevalence rates had changed, assess which factors affect prevalence and record disability status.
Methods: Hospital, general practice (GP) and laboratory records were searched to identify prevalent MS patients (alive and registered with a participating GP on 24 September 2009). Records were reviewed to confirm diagnoses applying Poser definite and probable and McDonald’s diagnostic criteria. Disability status (Expanded Disability Status scale [EDSS]) was recorded from records and questionnaires. Rates were standardised to the Scottish population. 
Results: 590 patients were found (Aberdeen 442, Orkney 82, Shetland 66). Mean age and disease duration were 53 and 19.4 years respectively. The standardised prevalence for Poser probable/definite MS per 100,000 were: combined area 248 (95%CI 229-269), Orkney 402 (95%CI 319-500), Shetland 295 (95%CI 229-375) and Aberdeen 229 (95%CI 208-250). McDonald’s diagnostic criteria gave a lower prevalence (202, 95%CI 198-206). Prevalence was highest in women (2.55:1, 95%CI 2.26-2.89) with about 1 in 170 women in Orkney affected. Prevalence was lowest in the most deprived socioeconomic group. 45% had significant disability (EDSS≥6). 













Much has been written about the epidemiology of MS in the north of Scotland. Between the 1950s and the 1980s, studies in Orkney and Shetland [1-6] showed a steady rise in the prevalence to about 190/100,000 (95%CI 150-280).  Studies in the 1970s and 1980s found a similar increase in the prevalence in Aberdeen and north-east Scotland from 127/100,000 (95%CI 116-137) to 178/100,000 (95%CI 162-185) [7-10] (Figure 1).  More recent studies in lowland Scotland revealed crude prevalence rates of 145/100,000 (95%CI 127-163) in Fife and Glasgow [11,12], 187/100,000 (95%CI 178-195) in Borders and Lothian [13] and 222/100,000 (95%CI 210-240) in Tayside [14]. 

Figure 1: Prevalence in Orkney, Shetland and Aberdeen over time

There have been no prevalence studies of multiple sclerosis (MS) in northern Scotland since the early 1980s despite this area having one of the highest rates in the world.  This study, therefore, aimed to measure the age-gender specific prevalence of (MS) in Aberdeen, Orkney and Shetland to assess whether it had changed over time and assess which factors might influence prevalence (socioeconomic status, diagnostic criteria, migration).  We also recorded disability status, which has not previously been reported in this area.

METHODS
Ethical approval was obtained from the North of Scotland Research Ethics Committee.

Geographical area:
The surveyed populations were that of Aberdeen city (latitude 57°9'N), the islands of Orkney (latitude 58°41'N-59°24'N) and Shetland (latitude 59°50'N-60°88'N). The neurology department of Aberdeen Royal Infirmary supplies all specialist neurological services in these areas including the only access to magnetic resonance imaging [MRI], neurophysiology tests such as visual evoked responses [VER] and biochemical analysis of cerebrospinal fluid [CSF] for oligoclonal bands.  In Shetland there are general physicians based at Gilbert Bain hospital who have access to a computer tomography (CT) scanner and in Orkney the Balfour hospital is managed by general practitioners and visiting general physicians with no brain imaging available.  

Patients were eligible if alive, resident in the study area and registered with a participating general practice (GP) on the prevalence day of 24 September 2009.  All general practices in Aberdeen (32), Orkney (14) and Shetland (10) were approached.  The baseline populations were calculated from GP data held by Information Service Division (ISD), Scotland [15]. All neurology and rehabilitation consultants in Aberdeen, general medical physicians in Shetland, the visiting consultants to Orkney and MS specialist nurses involved in the care of MS patients were informed about the project by letter.

Case ascertainment:
Prevalent cases were identified by: (i) searching electronic GP databases for patients registered on the prevalence day with a specified MS diagnostic code (READ code F20); (ii) searching hospital discharge data (ICD-10 code for MS G35) from 1999 for Aberdeen Royal Infirmary (ARI), Woodend hospital (a large rehabilitation facility), Gilbert Bain Hospital (Shetland) and the Balfour Hospital (Orkney), as well as the MS specialist nurse databases in Aberdeen and Shetland; (iii) searching the ARI laboratory results for positive CSF oligoclonal bands from 1999 and neurophysiology for abnormal visual evoked responses from 1973.  Radiology records were not accessible for case ascertainment.  Independent MS patient organisations supported the study in an advisory capacity and helped advertise the project.

Case definition:
A neurology research fellow and a supervised medical student reviewed the hospital records, GP records and laboratory data of all patients identified by the searches to confirm the diagnosis according to internationally accepted diagnostic criteria.  Patients were included if they satisfied Poser criteria for clinically definite, laboratory-supported definite, clinically probable, or laboratory-supported probable criteria or McDonald 2001 or the revised McDonald 2005 criteria [16,17,18]. Patients with clinically isolated syndromes were excluded unless they met McDonald 2005 criteria for MS.  In cases of doubt, a senior neurologist made the final decision. Some patients (n=81) taking part in a parallel genetics study [19] were examined by the research fellow. We recorded the sub-type of MS (relapse-remitting, secondary progressive and primary progressive) and disability status was scored using a modified Expanded Disability Status Scale (EDSS) [20] (mild 0-2.5, mild to moderate 3-5.5, moderate to severe 6-7.5 and severe 8-9.5) estimated from the patient records.

The Scottish Index of Multiple Deprivation (SIMD) [15] was used to analyse socioeconomic status. This index uses data from 31 indicators in different domains (income, employment, housing, health, education and access) and scores are allocated to postcode sectors in quintiles, the first quintile being the most deprived group and the fifth quintile the least. 

Questionnaire:
A subsequent postal questionnaire asked about: (i) level of disability using the modified EDSS; (ii) place and date of diagnosis to identify patients who migrated into the study area after diagnosis; (iii) employment status (See Figure S1, supplemental data). We worked with the GPs to identify all MS patients from the prevalent population suitable for invitation to complete the questionnaire such that patients who were unaware of their diagnoses or disputed it were not sent the questionnaire. Non-responders were sent a second questionnaire after four weeks.

Sample Size:
Based on the previous prevalence of about 190 per 100,000 from the 1980s we expected to find 480 MS patients in the combined study area using the Scottish population (June 2009) [21].  This gave more than 80% power to detect a 25% increase or decrease in prevalence over time at the 5% significance level.

Statistical methods:




Twenty-eight (87%) general practices in Aberdeen (population 205,446) agreed to participate in the survey, 13 in Orkney (93%, population 20,000) and 10 in Shetland (100%, population 22,656).  The searches identified 2,586 possible cases. This resulted in 782 possible MS patients, of whom 590 (420 females and 170 males) subsequently satisfied the diagnostic criteria (Figure 2). Most (573, [97%]) were identified from the GP records or the MS specialist nurse databases (Table S1, supplemental data).

Figure 2: Flowchart of case ascertainment and compilation of database.

There was no significant difference in mean age (p=0.42), mean age at first symptom onset (p=0.94) or mean age at diagnosis (p=0.94) between men and women with MS (Table 1).  The mean disease duration from first symptom was 19.4 years. There was no evidence that the age of first symptom onset had changed significantly compared to previous studies from this area (Table S2, supplemental data), but unfortunately previous studies had not reported age at diagnosis.  The most common sub-type was relapse-remitting MS [50%] (Table 1).

Table 1:  Demographic data of multiple sclerosis patients in the combined area of Aberdeen city, Orkney and Shetland
Demographic data	All patients	Men	Women
Number of Cases 	590	170 (29%)	420 (71%)
Mean age (years)	52.5 (SD 12.8)	53.8 (SD 12.8)	51.9 (SD 12.8)
Type of MS                      Relapse-Remitting 	294 (50%)	72 (42 %)	222 (53%)
Secondary Progressive 	237 (40%)	71 (42%)	166 (40%)
Primary Progressive 	59 (10%)	27 (16%)	32 (7%)
Mean age at diagnosis (years)	39.3 (SD 11.0)	40.9 (SD 10.9)	38.7 (SD 11.1)
Mean age at onset (first symptoms) (years)	33.2 (SD 11.0)	34.7 (SD 11.3)	32.6 (SD 10.9)
Disease duration from first symptoms (years)	19.4 (SD12.4)	19.1 (SD 13.2))	19.3 (SD12.1)
Disease duration from diagnosis (years)	13.2 (SD 10.5)	12.9 (SD 10.7)	13.3 (SD 10.4)
EDSS from records (n=590)			
Median score	5.0 (IQR  0-7)	6.0 (IQR 2-6.5)	3.5 (IQR 1-6.5)
EDSS patient reported (n=327)			
Median score	5.5 (IQR 1-6.5)	5.75 (IQR 0-6.5)	5.5 (IQR 0-7)






For the whole study area, the crude prevalence rate was 238/100,000 (95% CI 219-258) for all patients, 136/100,000 (CI 95% 117-158) for men (1 in 735) and 341/100,000 (95%CI 309-375) for women (1 in 293).  After direct standardisation to the Scottish population the overall rates increased slightly to 248/100,000 (95%CI 229-269) (Table 2). The age standardised female-to-male ratio was 2.55:1 (95%CI 2.26-2.89), with evidence of an increasing sex ratio in younger prevalent patients when analysed by birth cohort (Figure S2, supplemental data).  

Table 2: Crude- and age-gender standardised prevalence rates of Multiple Sclerosis patients in the combined area of Aberdeen city, Orkney and Shetland























In the three different study areas the overall standardised rates were 229/100,000 (95%CI 208-250) for Aberdeen, 402/100,000 (95%CI 319-500) for Orkney and 295/100,000 (95%CI 229-375) for Shetland (Table 3). Orkney had a significantly higher prevalence rate than Aberdeen (p=0.0001), as high as 1 in 171 for women, and the difference between Orkney and Shetland (p=0.06) and between Shetland and Aberdeen (p=0.08) approached significance.

Previous prevalence studies in these areas did not publish the age-gender structure of patients needed for standardisation. However, ISD data showed the age-gender population structures of the three study areas had not changed significantly from 1981 to 2009 allowing crude prevalence rates to be compared.  There were significant increases in prevalence in the overall study area, in Orkney and Shetland but not in Aberdeen compared to the previous prevalence studies from the 1980s (Table 3).

Region 	Sex	2009 Cases	2009 Local population	2009 Age-gender standardised Prevalence  per 100,000(95%CI)	2009 Crude Prevalence per 100,000 (95%CI)	1980s Cases	1980s Crude Prevalence per 100,000 (95% CI)	Difference in prevalence from 1980’s to 2009 per 100 000 (95%CI) 	P valuedifference
Overall	All	590	248102	248 (229-269)	238 (219-258)	495	201 (184-219) [5,6,10]	37    (11-63)	0.0005
Aberdeen	All	442	205446	229 (208-250)	215 (196- 236)	407	200 (181-220) [10]	15    (-13- 43)	0.28
	Men	130	103350	134 (119-151)	126 (105-149)	N/A			
	Women	312	102096	318 (306-356)	306 (273-341)	N/A			
Orkney	All	82	20000	402 (319-500)	410 (326-509)	43	224 (162-302) [5]	186  (75-300)	0.003
	Men	23	9897	226 (165-302)	232 (147-349)	10			
	Women	59	10103	569 (481-698)	584 (445-753)	33			
Shetland	All	66	22656	295 (229-375)	291 (225-371)	45	192 (140-257) [6]	99    (10-192)	0.03
	Men	17	11524	148 (102-207)	148 (86-236)	N/A			
	Women	49	11132	429 (367-547)	440 (326-582)	N/A			
Table 3: Crude and age-gender standardised prevalence rates of Multiple Sclerosis in different areas for 2009 and 1980/84
N/A – not available

Prevalence rates for the whole study area varied when applying different diagnostic criteria. Only 536 (91%) of patients satisfied Poser’s definite criteria, resulting in a crude prevalence of 219/100,000 (95%CI 215-224), whilst only 495 (84%) of patients satisfied McDonald criteria giving a prevalence of 202/100,000 (95%CI 198-206). The rates were identical for McDonald’s 2001 and 2005 criteria.  The most common reason for failure to satisfy McDonald criteria was the absence of magnetic resonance imaging [MRI] (Table S4, supplemental data).  No patients with clinically isolated syndromes satisfied McDonald 2005 criteria necessary for inclusion. A few patients (n=12, 11 Aberdeen, one Shetland) may have had MS clinically but did not satisfy any diagnostic criteria and were, therefore, excluded.

There was a statistically significant association between SIMD and prevalence rate (Chi-square 25.36, 4df, p=0.00004), with the lowest socioeconomic group having a prevalence about 2.5 times lower than the other groups, which were all similar (Table 4). The same pattern was seen when the analysis was restricted to Aberdeen only. Orkney and Shetland had no areas in the lowest SIMD quintile but showed no difference in prevalence over the upper four quintiles.  

Table 4:  Variation in prevalence of multiple sclerosis by socioeconomic status at postcode level
SIMD Quintile	Number of MS patients / Total population in each SIMD quintile*	Prevalence /100,000 (95% CI)	Odds ratio (95% CI)




5 (Least deprived)	193/79125	244 (210-278)	2.38 (1.90-3.64)
* No SIMD score was available for 6 patients in Orkney

Questionnaire results:
505 patients were sent questionnaires and 330 (66%) returned them. The median estimated EDSS from patient records (n=590) was 5 (interquartile range [IQR] 1 to 6.5) compared to 5.5 (interquartile range [IQR] 0 to 7) from self-reported questionnaire data (n=327) (Table S3, supplemental data). There was no statistically significant difference between the median EDSS in males and females (p=0.23). 46% (n=264) of patients were estimated from notes to be moderately to severely disabled (EDSS≥6) compared to 50% from the self reported questionnaire. In patients who had both notes-based and self-reported EDSS, there was a significant correlation between the two (Spearman’s rho=0.774, p<0.0001), and the median difference between the two was 0 (interquartile range -1 to1).

Thirty patients (5%) were residing in nursing, residential or care facilities on the prevalence day (mean age 62 years, SD13). Of these 25, four and one had secondary progressive, primary progressive and relapse-remitting MS respectively. Fewer MS patients of working age were employed (n=129, [47%] 95 relapse-remitting, 26 secondary progressive, 8 primary progressive) than the general population (85%) [24]. 57% of employed MS patients were working full-time and 43% part-time.

62% (n=203) of the 330 questionnaire respondents were native to the study area. Of the 127 non-natives, only 5% (n=16, seven Aberdeen, five Orkney, four Shetland) were diagnosed elsewhere before moving into the prevalence area.  Twenty-seven patients moved into the area before the age of 15 years (16 from Scotland, seven from England, three from elsewhere), whilst 100 migrated into the area after age 15 yrs (59 from Scotland, 32 other parts of United Kingdom, nine elsewhere).
DISCUSSION
We have shown that the prevalence of MS in northern Scotland has continued to increase since the early 1980s, particularly in Orkney where the rate remains the highest worldwide as indicated in previous studies.

Several possible reasons for the increase in prevalence over time need consideration including random variation, improved case-ascertainment, altered diagnostic criteria, improved diagnosis, migration of high risk people into the area, longer survival and an increase in incidence. Given the small island populations, the islands’ rates are more prone to chance fluctuations, which may partly explain why these showed the largest changes.  However, random variation is less likely to explain the smaller but highly statistically significant increase over time in the total study area.

The increase in prevalence is unlikely to be due to improved case ascertainment (our search strategies were similar to previous studies) or changes in diagnostic criteria since previous studies used older, less specific criteria [25], which would artifically inflate the previous prevalence figures not reduce them and included both possible and probable cases whereas we only included probable and definite cases.  Whilst there has been greater availability of specialist neurological services in the area over time, it is difficult to see how this could explain the large increase in prevalence, particularly on the islands.

Migration of pre-existing MS patients or those at high risk of developing MS into the study area is also unlikely to be an explanation of the rise in prevalence.  Only 5% of prevalent patients moved into the area after diagnosis.  Those who migrated into the area prior to diagnosis are unlikely to have brought with them a higher risk of MS.  In this group, those who came at a young age would take on the risk of the study area [26], whilst those who came later did not come from high risk areas.

Improved survival in people with MS over the past 30 years would increase prevalence and has been documented elsewhere [27].  However, again this is unlikely to explain all the increase.  Others have shown that the increased survival in MS has been proportional to the increased survival in the general population [28].  Scotland’s population survival has increased from 71 years in 1980 to 75 years in 2009 [29], implying that MS survival will have increased by about 1.5 years over the same time period given it was about 25 years in the 1980’s [30].  This falls short of the five year increased survival needed to explain the total prevalence rise in the whole study area if the incidence of MS had remained unchanged (assuming prevalence=disease survival x incidence).

The final cause of an increased prevalence would be an increased incidence of MS in the area as has been observed in other countries [31,32].  Although we did not perform an incidence study, it has been shown that an increasing female-to-male sex ratio is a good proxy for rising incidence [32,33] and our data did show such an effect both by five-year birth cohort within our total study group (Figure S2, supplemental data) and over time in prevalence studies from mainland northern Scotland, where the sex ratio has increased from 1.3:1 in the 1950s to 2.4:1 in 2009 (Table S5, supplemental data). So, it is highly likely that there has been an increase in incidence in this study area.  The cause of this increased incidence is unknown but purely genetic factors cannot account for the rising incidence over such a short period, which points towards an environmental factor.  Recent evidence has suggested a significant role for vitamin D in the aetiology of MS and, therefore, changes in vitamin D levels may play a role in the rising incidence but we did not measure vitamin D levels in our cohort.

We found a socioeconomic effect with a significantly lower rate of MS in the lowest socioeconomic category according to SIMD category, which has been seen in some but not all all previous studies [34,35].  In the UK where there is free access for all to a national health system, this is unlikely to be due to differential access to health services.  The ‘hygiene hypothesis’, suggests that the difference may be due to people in higher socioeonomic groups having less immunity or later exposure to viruses than people in the lower socioeconomic groups, rendering them more vulnerable to infection with viruses (such as Epstein Barr virus (EBV)) which has been implicated in the aetiology of MS.  Alternatively other factors such as time spent out doors or vitamin D may play a role but our study provided no direct data on these factors.  
We demonstrated a significant impact of MS at community level both in terms of disability and employment, particularly in the primary and secondary progressive patients as expected. There was good agreement between the estimated and self-reported EDSS, the latter being slightly higher probably because it was a more recent assessment.  Although the EDSS is widely used in MS research, it is largely focussed on mobility and, therefore, we may have under-estimated disability caused by other MS symptoms such as cognitive impairment and pain.

This main strengths of this project were the multiple sources used for case ascertainment and the thorough review of primary and secondary health care records to verify each diagnosis.  There were also some limitations. Some people with a false positive diagnosis of MS may have been included because most patients were not reviewed in person by the study team.  In particular,  there were a number of older patients diagnosed with MS before the widespread introduction of MRI who may have had other relapsing central nervous conditions that mimic MS.  However, this limitation applies to previous prevalence studies as well and we excluded patients in whom there was diagnostic uncertainty after a thorough review of their medical records. In addition, some people with MS may have been wrongly excluded from our study (false negative diagnoses). For example, our searches may have missed some patients with longstanding benign MS if they were not coded on GP databases, had not been in contact with an MS specialist nurse, and had not been admitted to hospital or had positive lumbar puncture after 1999.  Brain MRI reports were not availaible for electronic searching and resources did not allow this project to do door-to-door case ascertainment. It is difficult to know whether the numbers of false positive and false negative diagnoses would balance out but we suspect our final prevalence rate may be an underestimate.  Finally, despite using methods proven to increase response to postal questionnaires [36], the questionnaire response rate was less than we hoped.

In conclusion, we found that the prevalence of MS in this part of Scotland is very high and has risen over the past 30 years, especially in the northern islands. We believe this rise is due to a combination of factors but is largely due to a rise in incidence, whilst the disproportionate rise in the islands may relate to random fluctuation due to their small populations. The reasons for the very high prevalence in Orkney and Shetland remain unknown.  The development of a high quality long-term Scottish national register of incident patients will help determine the degree to which incidence is rising in Scotland and whether the incidence in the islands is significantly higher than elsewhere [37]. 
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